RxDoctor Payments DataLook up a doctor →

Sami Aboumatar, MD

Neurology · Austin, TXNPI 1760445407

Payments from drug & device makers

$592,564in general payments, 2019–2025

Across 591 payments — averaging $1002.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • SK Life Science, Inc.$194K
  • Aquestive Therapeutics, Inc.$106K
  • Sunovion Pharmaceuticals Inc.$97K
  • UCB SA$53K
  • Jazz Pharmaceuticals Inc.$49K
  • UCB Biosciences Inc.$42K
  • plus $51K from 37 others
$32,605in research payments, 2019–2025

Across 59 payments — averaging $552.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Neuropace, Inc.$19K
  • Aquestive Therapeutics, Inc.$9K
  • Jazz Pharmaceuticals Inc.$5K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
SK Life Science, Inc.135$194,089
Aquestive Therapeutics, Inc.19$105,779
Sunovion Pharmaceuticals Inc.98$97,460
UCB SA7$52,907
Jazz Pharmaceuticals Inc.25$49,431
UCB Biosciences Inc.10$41,755
UCB, Inc.98$27,436
Eisai Inc.16$11,234
GW Research Limited1$7,440
Greenwich Biosciences, Inc.7$1,935
AbbVie(2 entities)25$327
Livanova USA, Inc.26$326
Otter Pharmaceuticals, LLC10$275
Neuropace, Inc.3$198
Pfizer10$196
Amgen7$166
Novartis8$165
Medtronic5$125
Teva Pharmaceuticals USA, Inc.7$120
Takeda Pharmaceuticals U.S.A., Inc.7$111
Sumitomo Pharma America, Inc.12$101
Neurelis, Inc.5$100
Aucta Pharmaceuticals, Inc.8$87
Acadia Pharmaceuticals Inc3$79
Avanir Pharmaceuticals, Inc.4$75
Supernus Pharmaceuticals, Inc.4$72
Lundbeck LLC3$64
Lilly USA, LLC4$59
Argenx US, Inc.2$51
Catalyst Pharmaceuticals, Inc.3$50
Otsuka America Pharmaceutical, Inc.2$48
OWP Pharmaceuticals, Inc.2$36
Impel Pharmaceuticals Inc.2$34
Upsher-smith Laboratories LLC2$33
Zogenix Inc.2$32
Biohaven Pharmaceutical Holding Company Ltd.2$31
Immedica Pharma US, Inc.1$28
Biocodex, Inc.1$27
Idorsia Pharmaceuticals US Inc1$20
Ironshore Pharmaceuticals Inc.1$19
Biohaven Pharmaceuticals, Inc.1$16
Axsome Therapeutics, Inc.1$14
Collegium Pharmaceutical, Inc.1$14

How this compares

$592,564 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas →

Medicare billing

Part B allowed, 2024
$182,874
Medicare patients
386
Services billed
1,266

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Austin

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →